Result of AGM

RNS Number : 3304T
N4 Pharma PLC
24 March 2021
 

24 March 2021

N4 Pharma plc

("N4 Pharma" or the "Company")

 

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.

 

Resolution (*Special Resolution)

Total Shares Voted

Shares

%

 

 

For

Against

For

Against

 

 

 

 

 

 

1. To receive the annual report and audited accounts for the year ended 31 December 2020

20,289,075

 

20,222,189

 

66,886

 

99.67

 

0.33

 

2. To re-elect Chris Britten as a Director of the Company

20,286,756

 

20,153,341

 

133,415

 

99.34

 

0.66

 

3. To re-elect Luke Cairns as a Director of the Company

20,286,756

 

20,194,827

 

91,929

 

99.55

 

0.45

 

4. To re-elect John Chiplin as a Director of the Company

20,286,756

 

20,209,370

 

77,386

 

99.62

 

0.38

 

5. To re-appoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration

20,219,901

 

20,134,176

 

85,725

 

99.58

 

0.42

 

6. To authorise the Directors to allot shares

20,283,475

 

20,101,362

 

182,113

 

99.10

 

0.90

 

7* . To disapply pre-emption rights

20,250,090

 

20,123,051

 

127,039

 

99.37

 

0.63

 

 

 

Enquiries:

 

N4 Pharma plc


Nigel Theobald, CEO

Via IFC Advisory

Luke Cairns, Executive Director




SP Angel Corporate Finance LLP

Tel: +44(0)20 3470 0470

Nominated Adviser and Joint Broker


Matthew Johnson/Caroline Rowe (Corporate Finance)


Vadim Alexandre/Rob Rees (Corporate Broking)




Turner Pope Investments (TPI) Limited

Tel: +44(0)20 3657 0050

Joint Broker


Andy Thacker/Zoe Alexander




IFC Advisory Ltd

Financial PR

Graham Herring

Zach Cohen 

Tel: +44(0)20 3934 6630

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBGGDXBSDDGBS

Companies

N4 Pharma (N4P)
Investor Meets Company
UK 100